一名62岁男性患者，在停用芬戈莫德后出现脊髓病变，同时伴有播散性带状疱疹。
A 62-Year-Old Male Patient With Spinal Lesions Following Fingolimod Discontinuation in the Setting of Disseminated Shingles.
作者信息
Ko Michelle Y, Williamson Eric
机构信息
Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Neurology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
出版信息
Cureus. 2025 May 21;17(5):e84587. doi: 10.7759/cureus.84587. eCollection 2025 May.
Abstract
The association between the discontinuation of therapies and "rebound" multiple sclerosis (MS) activity has been frequently reported, yet is incompletely understood. We report an older male with previously well-controlled MS who was taken off his decade-long fingolimod treatment due to disseminated zoster infection, who subsequently experienced two severe MS exacerbations within six weeks. Though clinicians should consider possible confounding influences from infections such as varicella-zoster virus (VZV) and COVID-19, this case raised the most concern for suspicion of early fingolimod-associated rebound.
摘要
治疗中断与“反弹”型多发性硬化症（MS）活动之间的关联已被频繁报道，但尚未完全了解。我们报告了一名老年男性，他之前的MS病情控制良好，因播散性带状疱疹感染而停用了长达十年的芬戈莫德治疗，随后在六周内经历了两次严重的MS病情加重。尽管临床医生应考虑水痘-带状疱疹病毒（VZV）和COVID-19等感染可能产生的混杂影响，但该病例最令人担忧的是怀疑早期芬戈莫德相关的反弹。
相似文献
1
A 62-Year-Old Male Patient With Spinal Lesions Following Fingolimod Discontinuation in the Setting of Disseminated Shingles.一名62岁男性患者，在停用芬戈莫德后出现脊髓病变，同时伴有播散性带状疱疹。
Cureus. 2025 May 21;17(5):e84587. doi: 10.7759/cureus.84587. eCollection 2025 May.
2
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.免疫调节剂和免疫抑制剂治疗复发缓解型多发性硬化症的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3.
3
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.对首次出现提示多发性硬化症临床发作的患者使用疾病修饰药物进行治疗。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2.
4
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.免疫疗法治疗多发性硬化症的不良反应：一项网络荟萃分析。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD012186. doi: 10.1002/14651858.CD012186.pub2.
5
Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.打破循环：针对水痘-带状疱疹病毒的终生疫苗接种策略考量
Expert Rev Vaccines. 2025 Dec;24(1):556-569. doi: 10.1080/14760584.2025.2514527. Epub 2025 Jun 19.
6
Rituximab for people with multiple sclerosis.利妥昔单抗治疗多发性硬化症。
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013874. doi: 10.1002/14651858.CD013874.pub2.
7
Siponimod for multiple sclerosis.西尼莫德用于多发性硬化症。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013647. doi: 10.1002/14651858.CD013647.pub2.
8
Fatal visceral disseminated varicella zoster virus infection during initial remission induction therapy in a patient with lupus nephritis: a case report and review of the literature.狼疮性肾炎患者初始缓解诱导治疗期间发生致命性内脏播散性水痘-带状疱疹病毒感染：1例病例报告并文献复习
CEN Case Rep. 2025 Jun;14(3):477-485. doi: 10.1007/s13730-024-00950-7. Epub 2024 Dec 12.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中，如果患者出现以下症状和体征，可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.用于进展性多发性硬化症的免疫调节剂和免疫抑制剂：网状荟萃分析。
Cochrane Database Syst Rev. 2024 Sep 10;9(9):CD015443. doi: 10.1002/14651858.CD015443.pub2.
本文引用的文献
1
Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.芬戈莫德停药后反弹的频率及危险因素——一项回顾性研究
Mult Scler Relat Disord. 2024 Jan;81:105134. doi: 10.1016/j.msard.2023.105134. Epub 2023 Nov 11.
2
SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation.SARS-CoV-2 与多发性硬化症：疾病恶化的潜在风险。
Front Immunol. 2022 Apr 22;13:871276. doi: 10.3389/fimmu.2022.871276. eCollection 2022.
3
Rebound activity after fingolimod cessation: A case - control study.停药后西尼莫德的反弹活动：一项病例对照研究。
Mult Scler Relat Disord. 2022 Jan;57:103329. doi: 10.1016/j.msard.2021.103329. Epub 2021 Oct 13.
4
Factors associated with fingolimod rebound: A single center real-life experience.与芬戈莫德反弹相关的因素：一项单中心真实世界经验。
Mult Scler Relat Disord. 2021 Nov;56:103278. doi: 10.1016/j.msard.2021.103278. Epub 2021 Sep 26.
5
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.COVID-19 与多发性硬化症的新症状有关，而疾病修正疗法可以预防这些症状。
Mult Scler Relat Disord. 2021 Jul;52:102939. doi: 10.1016/j.msard.2021.102939. Epub 2021 May 5.
6
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.2019 年冠状病毒病（COVID-19）能否引发多发性硬化症恶化？一项回顾性研究。
Mult Scler Relat Disord. 2021 Jul;52:102947. doi: 10.1016/j.msard.2021.102947. Epub 2021 Apr 11.
7
Diagnosis and Treatment of Multiple Sclerosis: A Review.多发性硬化症的诊断与治疗：综述。
JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858.
8
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.全球多发性硬化症患病率上升：第三版多发性硬化症图谱的见解。
Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.
9
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.芬戈莫德反弹：临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
10
Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases.用奥瑞珠单抗治疗芬戈莫德停药后出现严重反弹并伴有短暂加重：两例报告。
Ther Adv Neurol Disord. 2019 May 6;12:1756286419846818. doi: 10.1177/1756286419846818. eCollection 2019.
Zotero 插件